Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study
Open Access
- 23 June 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 9 (10), 1190-1202
- https://doi.org/10.1002/sctm.20-0099
Abstract
Steroid-refractory chronic graft-vs-host disease (cGvHD) contributes to morbidity after allogeneic hematopoietic stem cell transplantation. Here, we report on 11 patients with severe, refractory cGvHD treated with repeated infusions of allogeneic bone marrow-derived mesenchymal stromal cells (MSC) over a 6- to 12-month period. Six patients responded to MSC treatment following National Institutes of Health response criteria, accompanied by improvement in GvHD-related symptoms and quality of life. This response was durable, with systemic immunosuppressive therapy withdrawn from two responders, and a further two free from steroids and tapering calcineurin inhibitors. All responders displayed a distinct immune phenotype characterized by higher levels of naïve T cells and B cells before treatment compared with the nonresponders, and a significantly higher fraction of CD31+ naïve CD4+ T cells. MSC treatment was associated with significant increases in naïve T cells, B cells, and Tregs 7 days after each infusion. Skin biopsies showed resolution of epidermal pathology. CXCL9 and CXCL10 showed differential responses in responder and nonresponder patients. Our data support the use of MSC infusions as treatment for steroid-refractory cGvHD with durable responses. We propose CXCL9 and CXCL10 as early biomarkers for responsiveness to MSC treatment. Our results highlight the importance of the MSC recipient immune phenotype in promoting treatment response. This trial was registered at www.ClinicalTrials.gov as #NCT01522716.Keywords
Funding Information
- Karolinska Institutet
- Tobias Foundation
- Swedish Society of Medicine
- Cancerföreningen i Stockholm
- Stockholms Läns Landsting (20110152)
- VINNOVA (2010-00501)
- Swedish Research Council (K2011-??X-20742-04-6)
- Cancerfonden (11 0315)
- Karolinska Institutet
- Svenska Läkaresällskapet
- Cancerföreningen i Stockholm
- Stockholms Läns Landsting (20110152)
- VINNOVA (2010‐00501)
- Vetenskapsrådet (K2011‐??X‐20742‐04‐6)
- Cancerfonden (11 0315)
This publication has 53 references indexed in Scilit:
- Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical TrialsPLOS ONE, 2012
- Standardizing immunophenotyping for the Human Immunology ProjectNature Reviews Immunology, 2012
- New Lives Given by Cell Death: Macrophage Differentiation Following Their Encounter with Apoptotic Leukocytes during the Resolution of InflammationFrontiers in Immunology, 2012
- Thymic T-cell development in allogeneic stem cell transplantationBlood, 2011
- Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trialHaematologica, 2011
- Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host DiseaseTransplantation and Cellular Therapy, 2011
- Reduced Mortality after Allogeneic Hematopoietic-Cell TransplantationNew England Journal of Medicine, 2010
- Mesenchymal stem cell as salvage treatment for refractory chronic GVHDBone Marrow Transplantation, 2010
- Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor functionJournal of Translational Medicine, 2009
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999